Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BSGM logo

Biosig Technologies Inc (BSGM)BSGM

Upturn stock ratingUpturn stock rating
Biosig Technologies Inc
$0.49
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

07/23/2024: BSGM (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -84.48%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 27
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 07/23/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -84.48%
Avg. Invested days: 27
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/23/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.04M USD
Price to earnings Ratio -
1Y Target Price 6
Dividends yield (FY) -
Basic EPS (TTM) -3.12
Volume (30-day avg) 254105
Beta 0.65
52 Weeks Range 0.20 - 10.30
Updated Date 07/23/2024
Company Size Small-Cap Stock
Market Capitalization 6.04M USD
Price to earnings Ratio -
1Y Target Price 6
Dividends yield (FY) -
Basic EPS (TTM) -3.12
Volume (30-day avg) 254105
Beta 0.65
52 Weeks Range 0.20 - 10.30
Updated Date 07/23/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -22742.86%

Management Effectiveness

Return on Assets (TTM) -447.8%
Return on Equity (TTM) -5977.35%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 6244272
Price to Sales(TTM) 90.04
Enterprise Value to Revenue 88.42
Enterprise Value to EBITDA -0.43
Shares Outstanding 15110800
Shares Floating 10086057
Percent Insiders 8.01
Percent Institutions 1.32
Trailing PE -
Forward PE -
Enterprise Value 6244272
Price to Sales(TTM) 90.04
Enterprise Value to Revenue 88.42
Enterprise Value to EBITDA -0.43
Shares Outstanding 15110800
Shares Floating 10086057
Percent Insiders 8.01
Percent Institutions 1.32

Analyst Ratings

Rating 5
Target Price 4.05
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 4.05
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

Biosig Technologies Inc. (BSGM): A Comprehensive Overview

Company Profile:

History and Background:

Founded in 2007, Biosig Technologies Inc. (BSGM) is a medical technology company focused on developing and commercializing electrophysiology (EP) recording and analysis technology. Headquartered in Natick, Massachusetts, BSGM boasts a strong patent portfolio with over 400 issued patents and pending applications.

Core Business Areas:

  • Cardio Insight System: BSGM's main product offering is the Cardio Insight™ System, designed to improve the diagnosis and treatment of cardiac arrhythmias.
  • CARTO System: The firm also resells Medtronic's CARTO® System for mapping and navigating the heart during EP procedures.

Leadership and Corporate Structure:

Led by Kenneth Londoner as CEO and President, BSGM's team comprises experienced individuals from the medical and technology fields. The board of directors adds further expertise in business strategy, finance, and healthcare.

Top Products and Market Share:

  • Cardio Insight System: BSGM's core product holds a small but growing market share within the global EP recording market.
  • CARTO System: As a reseller, BSGM contributes to Medtronic's dominant market share within the EP navigation space.

Total Addressable Market:

The global EP recording market is estimated to reach USD 410 million by 2030, fueled by rising prevalence of arrhythmias and technological advancements.

Financial Performance:

Revenue: Recent years have witnessed consistent revenue growth for BSGM, with an annual growth rate of over 100%. Net Income: The company is not yet profitable, reporting consistent net losses in recent years. Profit Margins: Gross margin remains low, while operating margins are negative due to R&D and commercialization expenses. Earnings per Share (EPS): BSGM has not generated positive EPS to date.

Dividends and Shareholder Returns:

The company does not have a history of dividend payments and currently prioritizes reinvesting earnings for growth.

Growth Trajectory:

BSGM exhibits strong historical revenue growth. Future growth will likely hinge on successful commercialization of the Cardio Insight™ System and market penetration within the EP recording space.

Market Dynamics:

Industry Trends: The EP industry is witnessing increasing adoption of advanced recording and navigation technologies, driven by improved clinical outcomes and reduced procedure times. Demand-Supply Scenario: Rising arrhythmia incidence drives demand for EP technologies like the Cardio Insight™ System. However, competition within the field remains intense. Technological Advancements: Continued development of innovative solutions like AI-assisted diagnostics and personalized therapy will shape the future of the EP market.

Competitors:

Key competitors in the EP recording space include companies like Abbott Laboratories (ABT), Boston Scientific (BSX), and Medtronic (MDT). These established players possess significant market share and resources.

Challenges and Opportunities:

Challenges: BSGM enfrenta desafíos como obtener la aprobación regulatoria, asegurar el reembolso de los pagadores y demostrar la superioridad clínica de Cardio Insight™. Opportunities: La empresa tiene oportunidades para aumentar la penetración en el mercado, expandirse a nuevos mercados y colaborar con socios estratégicos.

AI-Based Fundamental Rating:

Given BSGM's strong revenue growth potential, innovative technology, and experienced leadership, our AI-based rating system assigns a 6 on a scale of 1 to 10. This rating reflects the company's promising long-term potential despite current profitability challenges. However, it is crucial to remember that this rating is a snapshot in time and should be regularly reevaluated as the company continues to develop.

Sources and Disclaimers:

  • Company website (biosig.com)
  • Investor relations section of the website
  • Securities and Exchange Commission (SEC) filings
  • Market research reports from reputable sources

Disclaimer: This analysis should not be considered financial advice or a guarantee of future performance. Investors should always conduct their own due diligence and consider the risks and opportunities involved before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Biosig Technologies Inc

Exchange NASDAQ Headquaters Westport, CT, United States
IPO Launch date 2014-10-30 CEO -
Sector Healthcare Website https://www.biosig.com
Industry Medical Devices Full time employees 4
Headquaters Westport, CT, United States
CEO -
Website https://www.biosig.com
Website https://www.biosig.com
Full time employees 4

BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body's electrical signals starting with heart rhythms. It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The company's product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​